Latest Advanced Prostate Cancer News2017-10-19T10:43:14-04:00

Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer *

Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very [...]

Using CT Scans to Predict A Pending Spinal Cord Compression in Men With Castration-Resistant Prostate Cancer *

CT scans are often performed in the process of monitoring of advanced prostate cancer disease progression. One of the most serious impacts of advanced prostate cancer is spinal compression, which can lead to paralysis and [...]

Detecting Prostate Cancer Cells in Blood Can Give An Early Warning of Treatment Failure and Shorten Clinical Trials

There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is [...]

A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer

Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy [...]

AdVance Transobturator Male Sling for Post-Prostatectomy Incontinence – A Retrospective Study of Its Efficacy *

One of the more difficult problems faced by some men treated with surgery as their primary treatment modality is post-prostatectomy incontinence (PPI). PPI can affect the quality of life for both men successfully treated as [...]

Coming Back to Continue the Blog and New Data Disclosed on Enzalutamide at the Plenary Session at the 2015 European Association of Urology Congress

Before I get into the meat of today’s post about enzalutamide, I want to briefly make some personal comments about my absence from this blog. As I had mentioned I have been diagnosed with a [...]

Go to Top